0000000000461074

AUTHOR

Flora E. Van Leeuwen

showing 5 related works from this author

Effect of genetic variation in CYP450 on Gonadal impairment in a European cohort of female childhood cancer survivors, based on a candidate gene appr…

2021

Background: Female childhood cancer survivors (CCSs) carry a risk of therapy-related gonadal dysfunction. Alkylating agents (AA) are well-established risk factors, yet inter-individual variability in ovarian function is observed. Polymorphisms in CYP450 enzymes may explain this variability in AA-induced ovarian damage. We aimed to evaluate associations between previously identified genetic polymorphisms in CYP450 enzymes and AA-related ovarian function among adult CCSs. Methods: Anti-Müllerian hormone (AMH) levels served as a proxy for ovarian function in a discovery cohort of adult female CCSs, from the pan-European PanCareLIFE cohort (n = 743

OncologyInfertilityCancer ResearchCandidate genemedicine.medical_specialtyendocrine systemendocrine system diseasesMedizinAnti-Müllerian hormoneArticleHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Childhood cancer survivors03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingInterquartile rangeInternal medicineGenetic variationGenetic modelmedicineChemotherapyFertility preservationRC254-282030304 developmental biology0303 health sciencesbiologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensAnti-Müllerian hormonemedicine.diseaseOvarian functionCytochrome P450 genesWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthOncology030220 oncology & carcinogenesisCohortbiology.proteinCandidate gene approachbusinessGeneral Economics Econometrics and FinanceCancers
researchProduct

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

2012

Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian …

Oncologyendocrine system diseases[SDV]Life Sciences [q-bio]Càncer d'ovariDCN PAC - Perception action and controlCohort StudiesBreast cancer0302 clinical medicinebrca1brca2Odds RatioGenetics (clinical)ComputingMilieux_MISCELLANEOUSOvarian NeoplasmsGenetics0303 health scienceseducation.field_of_studyBRCA1 ProteinHazard ratioMiddle Aged3. Good healthovarian cancer030220 oncology & carcinogenesisFemaleAdultHeterozygotemedicine.medical_specialtyHereditary cancer and cancer-related syndromes Genetics and epigenetic pathways of disease [ONCOL 1]PopulationSingle-nucleotide polymorphismBiologyOvarian Neoplasms - geneticsPolymorphism Single NucleotideArticleCàncer de mama03 medical and health sciencesBreast cancerGermline mutationSDG 3 - Good Health and Well-beingTranslational research [ONCOL 3]Ovarian cancerInternal medicineGeneticsmedicineHumansGenetic Predisposition to Diseaseddc:610Genetics and epigenetic pathways of disease Translational research [NCMLS 6]educationRetrospective Studies030304 developmental biologyBRCA2 ProteinHereditary cancer and cancer-related syndromes [ONCOL 1]associationRetrospective cohort studysnpOdds ratioBRCA1 Protein - geneticsmedicine.diseaseBRCA2 Protein - geneticsMutationOvarian cancerbrca2; snp; brca1; association; ovarian cancer
researchProduct

European code against cancer 4th edition: 12 ways to reduce your cancer risk

2015

AbstractThis overview describes the principles of the 4th edition of the European Code against Cancer and provides an introduction to the 12 recommendations to reduce cancer risk. Among the 504.6 million inhabitants of the member states of the European Union (EU28), there are annually 2.64 million new cancer cases and 1.28 million deaths from cancer. It is estimated that this cancer burden could be reduced by up to one half if scientific knowledge on causes of cancer could be translated into successful prevention. The Code is a preventive tool aimed to reduce the cancer burden by informing people how to avoid or reduce carcinogenic exposures, adopt behaviours to reduce the cancer risk, or t…

Cancer Researchmedicine.medical_specialtyQuality Assurance Health CareEpidemiologyUterine Cervical NeoplasmsCancer preventionCauses of cancerCancer screeningBreast cancerRisk FactorsEnvironmental healthCancer screeningmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unionPreventive healthcaremedia_commonCervical cancerCancer risk factorsCancer preventionbusiness.industryCancermedicine.diseaseEuropeOncology1117 Public Health And Health ServicesWorking Groups of Scientific ExpertsPractice Guidelines as TopicFemalebusiness1112 Oncology And Carcinogenesis
researchProduct

Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study.

2021

BackgroundSurvivors of childhood cancer are at risk of subsequent primary neoplasms (SPNs), but the risk of developing specific digestive SPNs beyond age 40 years remains uncertain. We investigated risks of specific digestive SPNs within the largest available cohort worldwide.MethodsThe PanCareSurFup cohort includes 69 460 five-year survivors of childhood cancer from 12 countries in Europe. Risks of digestive SPNs were quantified using standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence.Results427 digestive SPNs (214 colorectal, 62 liver, 48 stomach, 44 pancreas, 59 other) were diagnosed in 413 survivors. Wilms tumour (WT) and Hodgkin lymphoma (HL) survivors…

medicine.medical_specialtyColorectal cancerPopulation03 medical and health sciences0302 clinical medicineInternal medicineEpidemiology of cancerCOLORECTAL CANCER SCREENINGmedicineCumulative incidence030212 general & internal medicineGastrointestinal cancerFamily historyeducation610 Medicine & healthGASTROINTESTINAL CANCERCOLORECTAL CANCEReducation.field_of_studybusiness.industryIncidence (epidemiology)Gastroenterologymedicine.disease030220 oncology & carcinogenesisCohortCANCER EPIDEMIOLOGYbusiness360 Social problems & social servicesGut
researchProduct

Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Coho…

2009

Abstract Background: Several reproductive and hormonal factors are known to be associated with ovarian cancer risk in the general population, including parity and oral contraceptive (OC) use. However, their effect on ovarian cancer risk for BRCA1 and BRCA2 mutation carriers has only been investigated in a small number of studies. Methods: We used data on 2,281 BRCA1 carriers and 1,038 BRCA2 carriers from the International BRCA1/2 Carrier Cohort Study to evaluate the effect of reproductive and hormonal factors on ovarian cancer risk for mutation carriers. Data were analyzed within a weighted Cox proportional hazards framework. Results: There were no significant differences in the risk of ova…

AdultOncologymedicine.medical_specialtyendocrine system diseasesSterilization TubalEpidemiologyPopulationCohort StudiesPregnancyRisk FactorsInternal medicinemedicineHumanseducationProportional Hazards ModelsBRCA2 ProteinOvarian NeoplasmsGynecologyTubal ligationeducation.field_of_studyBRCA1 Proteinbusiness.industryProportional hazards modelHazard ratioCancerMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsParityOncologyMutationFemalebusinessRisk assessmentOvarian cancerContraceptives OralCohort studyCancer Epidemiology, Biomarkers & Prevention
researchProduct